Biodexa Pharmaceuticals has enrolled the initial two subjects in the placebo-controlled Phase III Serenta study of an oral ...

August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous ...

Juvenile polyposis syndrome (JPS) refers to a condition in which there are multiple benign polyps in the colon, or large intestine. Polyps are outgrowths occurring on the inside of a hollow organ.

We present here a case of attenuated familial adenomatous polyposis (AFAP) with a family history of desmoids and thyroid tumors. This patient had no colonic polyps but did have multiple desmoids ...

Familial adenomatous polyposis (FAP) is caused by mutations in the APC gene and 2 different, or biallelic mutations, in the MUTYH gene. However, not all patients with colorectal polyposis are ...

Patients with germline pathogenic variants (PVs) in APC develop tens (attenuated familial adenomatous polyposis [AFAP]) to innumerable (classic FAP) adenomatous polyps in their colon and are at ...

The first entity (BTP syndrome type 1) consists of patients who have glioma and colorectal adenomas without polyposis (non-FAP cases), and their siblings with glioma and/or colorectal adenomas. For ...

Biodexa Pharmaceuticals ( (BDRX) ) just unveiled an announcement. On August 18, 2025, Biodexa Pharmaceuticals announced the enrollment of the first two patients in its pivotal Phase 3 Serenta trial ...

Reference Valverde-Monge M, Barroso B, Ortega-Martin L, et al. Exploring adherence to treatment in nasal polyposis. J Investig Allergol Clin Immunol. 2022;32 (4):299-301. doi:10.18176/jiaci.0752 ...

Biodexa Pharmaceuticals, a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced the activation of the ...